Why the study?
Do lipid-lowering and anti-inflammatory therapies induce coronary atherosclerosis plaque regression?
Do lipid-lowering and anti-inflammatory therapies induce coronary atherosclerosis plaque regression?
This scientific statement highlights that while high-dose statins have the most robust evidence for inducing coronary plaque regression, non-statin lipid-lowering and anti-inflammatory drugs also show potential, although absolute volume changes remain limited.
Answers are grounded in this paper and cite their sources.
Endorses intensified lipid-lowering and anti-inflammatory therapy for plaque stabilization; extends evidence to fibro-lipidic regression despite limited absolute volume change.
The present is the second part of a scientific statement supported by the European Association of Preventive Cardiology, the European Association of Cardiovascular Imaging of the ESC, the ESC Working Group on Atherosclerosis and Vascular Biology, and the ESC Working Group on Cardiovascular Pharmacotherapy regarding evidence on atherosclerosis regression. This second part is focused on evidence exploring the effect of different therapies, from lipid-lowering to anti-inflammatory drugs, on atherosclerosis progression. Although statins-particularly at higher doses-have the most extensive data supporting their effect on atherosclerosis, mainly resulting in fibro-lipidic plaque volume regression, emerging data suggest that non-statin lipid-lowering drugs and anti-inflammatory therapies may also affect the natural history of atherosclerosis. However, it should be noted that the absolute change in coronary plaque volume is generally limited, underscoring the need for further research on pharmacological intervention targeting atherosclerosis for early identification and treatment of patients at higher risk.
No takes yet. Share an insight, caveat, or question.
Conte et al. (2025) conducted a review in Coronary atherosclerosis. Lipid-lowering and anti-inflammatory drugs was evaluated on Atherosclerosis progression and plaque volume regression. Statins, non-statin lipid-lowering drugs, and anti-inflammatory therapies promote fibro-lipidic plaque volume regression, though absolute changes in coronary plaque volume remain limited.
Synapse has enriched 10 related papers. Consider them for comparative context: